Business
Press Release Mar 16 2026
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome".
About this update from Zydus Lifesciences Limited
[{"type":"text","content":" Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2026, titled \"Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome\". View Attachment","length":380,"tagName":"div"}]